Lemtrada (alemtuzumab) improved disability scores in MS pts

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Lemtrada (alemtuzumab) improved disability scores in MS pts

Postby MSUK » Wed Apr 25, 2012 2:25 am

Lemtrada (alemtuzumab) improved disability scores in MS patients over Rebif

Image

Genzyme, a Sanofi company , reports today additional data from the Phase III CARE-MS II trial. Accumulation of disability was significantly slowed in patients with multiple sclerosis (MS) who were treated with alemtuzumab versus Rebif(R) (high dose subcutaneous interferon beta-1a), as measured by the Expanded Disability Status Scale (EDSS), a standard assessment of physical disability progression.

In addition, significant improvement in disability scores was observed in some patients treated with alemtuzumab from baseline and compared to patients treated with Rebif, suggesting a reversal of disability in these patients. In the trial, patients with pre-existing disability treated with alemtuzumab were more than twice as likely to experience a sustained reduction in disability than patients given Rebif. Genzyme is developing alemtuzumab in MS in collaboration with Bayer HealthCare....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 1985
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Campath (Lemtrada, Alemtuzumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users